Recently, during an institutional investor meeting, Shanghai Medicilon Inc. (688202.SH) stated that its overseas business expansion and operations are actively and orderly being carried out. The company will expand into core overseas industrial regions, strengthen the development of its business team, increase communication between overseas BD and domestic research teams, and gradually establish a market sales system that adapts to overseas market competition. In addition, the company will actively participate in overseas industry conferences and increase the regularity of its research team's expansion.
Currently, the company has put into use its research and development laboratory in Boston, USA, covering chemistry, biology, and animal experiments. The Boston laboratory will serve as a strategic base and take a solid step towards global deployment. The Boston laboratory will work in conjunction with various domestic R&D centers to realize differentiated development through resource sharing, and focus on meeting the growing demands of overseas customers. It will continue to strengthen communication and cooperation with global partners, provide effective support for the business expansion of European and American customers, strive to gradually increase the proportion of the company's overseas business, and provide new ideas, directions, and momentum for the company's development and growth while accelerating its global layout and seeking more development opportunities.
